权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Targeting the HIV/SIV reservoir at time of ART initiation

在开始 ART 时针对 HIV/SIV 病毒库

基本信息

批准号：
10222532
负责人：
Afamefuna Okoye
金额：
$ 69.66万
依托单位：
OREGON HEALTH & SCIENCE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-07-23 至 2024-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10222532
关键词：
Acute Address Agonist Alleles Antigens Antiviral Agents Bar Codes Biological Markers Blood CD4 Positive T Lymphocytes CD8-Positive T-Lymphocytes CD8B1 gene Cells Clinic Clinical Trials Collaborations Data Development Disease Progression Disease remission Dose Economic Burden Exploratory/Developmental Grant for Diagnostic Cancer Imaging Frequencies Gene Expression Genetic Transcription Goals Grant HIV HIV Infections Health Human Immune Immune response In Vitro Individual Infection Interleukin-15 Interruption Intervention Kinetics Lead Life Life Expectancy Location Lymphoid Tissue Macaca Macaca mulatta Measurable Mediating Modeling Newly Diagnosed Pilot Projects Production Prognosis Protein Kinase C Relapse Reporting Risk SIV Safety Sampling Shock Societies T cell response Techniques Testing Therapeutic Effect Time Tissues Toxic effect Treatment Efficacy Variant Viral Viral Antigens Viral Cytopathogenic Effect Viral reservoir Virus Virus Activation Virus Diseases Virus Replication acute infection antiretroviral therapy base cell killing clinically relevant cytotoxic CD8 T cells effector T cell efficacy testing improved in vivo latent HIV reservoir migration nonhuman primate novel novel strategies novel therapeutic intervention prevent purge simian human immunodeficiency virus social stigma success treatment effect viral rebound

项目摘要

PROJECT SUMMARY Antiretroviral therapy (ART) has dramatically improved the prognosis of people living with human immunodeficiency virus (HIV) infection. However, ART alone cannot eradicate the infection and therefore, daily treatment must be maintained for life to prevent relapse of uncontrolled viral replication and resumption of disease progression. Unfortunately, in addition to persistent stigma associated with HIV infection, lifelong treatment entails both health risks to treated individuals and a significant economic burden to society. As such, there is a desperate need to develop novel therapeutic interventions that can cure HIV infection. It is now well established that initiation of ART in the first days/weeks after infection does not prevent the establishment of a long-lived viral reservoir, although it is effective at reducing its size. Another strategy aimed at reducing the reservoir is to induce HIV gene expression in individuals on suppressive ART with the goal of eliminating latently infected cells, which could ultimately lead to virus eradication. However, purging the HIV reservoir not only requires the induction of viral replication by latency-reversing agents (LRA) but also the elimination of these reactivating latently-infected cells by either viral cytopathic effects or immune cell-mediated killing, so called “shock and kill”. This killing is often inefficient when LRAs are administered to HIV-infected individuals after several years of ART, possibly due to low level antigen expression, negative impact of LRAs on clearance mechanisms or the low frequencies of effective HIV-specific CD8+ T cells. Here we propose to evaluate a novel strategy in which an LRA is administered together with ART during acute infection. We believe this “window of opportunity” when the immune responses are still present and the latent reservoir is easier to reactivate will improve the efficacy of the “shock and kill HIV” approach to a cure. To address this, we will use GSK445A, a stabilized Ingenol-B based Protein Kinase C agonist (PKC) that we have shown can induce HIV/SIV transcription in vitro and in vivo in SIV-infected rhesus macaques (RM) on ART without significant toxicity. We propose to further optimize our strategy by evaluating if combining GSK445A with IL-15 can enhance the therapeutic effect. As such, the goal of this R01 is to determine whether administering this potent LRA during acute SIV infection, at the time of ART initiation, will delay or prevent viral rebound after ART cessation. The demonstration of therapeutic efficacy in this project will provide strong impetus for assessment of this concept in recently infected HIV+ individuals.

项目总结